Gilead’s HIV Pipeline Targets Needs & Advances Public Health
Gilead Sciences has revealed a range of positive data from its HIV research pipeline, showcasing its innovative treatment strategies....
AbbVie, OSE Partner for Novel Anti-Inflammatory Antibody
AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the...
SCRI & AstraZeneca Forge Alliance for Cancer Research Tech
Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca...
FDA Priority Review for Epcoritamab in Refractory Lymphoma
Genmab A/S and AbbVie have received Priority Review from the FDA for epcoritamab-bysp, a bispecific antibody for the treatment...
Mandara III Data: Fasenra Aids EGPA Remission, NEJM Reports
Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with eosinophilic granulomatosis with polyangiitis (EGPA)...
Biktarvy by Gilead: FDA Approval for Resistant HIV Cases
Gilead Sciences, Inc. has announced the FDA’s approval of an expanded indication for Biktarvy® to treat people with HIV...
Merck’s Keytruda Gets Positive CHMP Opinion for NSCLC Therapy
Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Xolair’s NEJM Phase III Data: Hope for Multiple Food Allergies
Genentech announced key findings from Stage 1 of the NIH-sponsored Phase III OUtMATCH study, published in the New England...
Silence Therapeutics Nabs $10M From AstraZeneca Phase 1 Start
Silence Therapeutics plc, a biotechnology company specializing in RNA interference (RNAi) therapies, has announced the initiation of a Phase...
Worldwide Clinical Trials Trials Upgrades Unit Pharmacy for Client Efficiency
Worldwide Clinical Trials has enhanced its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, with a significant expansion completed...